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ABSTRACT A critical appraisal and clinical application of Civardi G, Vallisa D, Berte R, et al. Ultrasound-guided fine needle 
biopsy of the spleen: high clinical efficacy and low risk in a multicenter Italian study. Am J Hematol. 2001 Jun;67(2):93-9. 
doi:10.1002/ajh.1085 
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Clinical Context 
The patient was a middle-aged man, admitted from the ED for persistent abdominal pain and bloody diarrhea. He 
had been given oral vancomycin by an outside hospital ED about a week prior to treat C. difficile colitis, but his 
symptoms had not improved. The patient had a history of recurrent C. difficile infections, Crohn's disease, and a 
small splenic mass. 
The patient was admitted into isolation on a general practice (GP) floor and both the gastroenterology (GI) and 
infectious disease teams were consulted. His C. difficile toxin was negative and he was started on IV Solu-Medrol 
(methylprednisolone) for his Crohn's disease. After four days with no response to the steroids GI recommended 
switching to a TNF-alpha inhibitor. However, due to the concern that the splenic mass was a lymphoma, GI wanted 
a definitive diagnosis before proceeding. On hospital day five, both surgery and interventional radiology (IR) were 
consulted about getting a definitive diagnosis. Surgery did not consider the patient a surgical candidate because of 
his active inflammation and steroid use, and they recommended consulting IR. IR would not do a biopsy due to 
concern that the bleeding risk was too high. Over the next three days the different departments debated the best 
course of action, and the patient grew increasingly frustrated as he was concerned about the splenic mass and felt 
it was not being addressed. On hospital day nine he was noted to have an increased WBC count, so a stool sample 
was taken for C. difficile toxin. That night he left against medical advice (AMA) to “seek care elsewhere.” 
The next day his C. difficile toxin came back positive, so he was called to come back into the hospital for treatment 
and he was readmitted. While the patient began treatment for the C. difficile, the team heard about a “cowboy” in 
the IR department who would often attempt procedures other providers had refused. This doctor agreed to 
consider trying the biopsy after seeing the mass firsthand on the IR table. The patient was very happy the mass 
was being addressed and was not concerned with the risks of the biopsy. The fine needle splenic biopsy was 
performed 14 days after initial presentation to the ED with a 20 gauge needle; four specimens were gathered, and 
no complications occurred. 
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Clinical Question 
Is the complication rate of image-guided percutaneous splenic biopsies overestimated by physicians compared to the complication 
rate of solid abdominal organ biopsies? 
Research Article 
Civardi G, Vallisa D, Berte R, et al. Ultrasound-guided fine needle biopsy of the spleen: high clinical efficacy and low risk in a 
multicenter Italian study. Am J Hematol. 2001 Jun;67(2):93-9. doi:10.1002/ajh.1085 
Literature Review 
This article was chosen for review by searching the PubMED database for articles containing the phrases “splenic biopsy” and 
“spleen biopsy.” Studies were then excluded based on sample size (<100 patients) and whether they addressed the clinical question. 
Among the remaining articles was a meta-analysis conducted by McInnes, Kielar, and Macdonald in 20111. This meta-analysis 
included a significant number of the remaining studies and seemed to encapsulate the extent of current research on image-guided 
splenic biopsies. The complication rate arm of this meta-analysis included nine studies with a total of 859 splenic biopsies (fine 
needle and core biopsies). Of the included studies, “Ultrasound-Guided Fine Needle Biopsy of the Spleen” by Civardi et al. 
contributed over half of the biopsies (453/859) and had the second highest STROBE score of 171-3. This paper was chosen for critical 
appraisal because it is a driving force in the current understanding of the risks of image-guided splenic biopsies. 
Civardi et al. concluded the overall complication rate for splenic biopsies “was low (but not negligible), with a percentage of 
complications less than 1% and no deaths”2. The study also acknowledges that splenic biopsies are still widely considered to be 
dangerous by most physicians especially in the US. 
The meta-analysis reported the major and overall complication rates for splenic biopsies to be 2.2% and 4.2%1. The meta-analysis is 
in alignment with Civardi et al. and concludes that the complication rate for splenic biopsies in the current standard of practice is 
comparable to those for both liver (0.5-3.3%) and kidney biopsies (0.7-6.3%)1. This is unsurprising because the Civardi study 
contributed most of the data for the analysis. The study also notes the morbidity and mortality of splenic biopsies is considerably 
lower than the most likely alternatives, splenectomies1. 
Additionally, in a study completed after the meta-analysis, which looked at 137 patients with isolated splenomegaly undergoing CT-
guided fine-needle biopsy, Tokue et al. reported only three adverse events4. This study is particularly valuable because it may be 
more relevant to modern biopsy techniques, helping to confirm the results from the meta-analysis and older studies1,5. 
Critical Appraisal 
While this study enjoys the advantage of having the largest number of biopsies performed, it has significant flaws. The first major 
disadvantage of this study is that it was designed as a retrospective review. This leads to the problem that the patients were not 
randomized, and there were no control groups. Another problem with the study methodology is a lack of selection criteria for the 
centers. The only information about how the locations were selected was that they must have had at least 10 years of experience 
using this biopsy technique. This significantly impacts the validity and how generalizable the study is because there is no way to 
know if this includes all the Italian centers that have been open for at least ten years, or whether they were chosen based on their 
low complication rates. A further problem with the choice of cases is that there are no criteria for the inclusion of individual cases. 
Chosen cases could include the first cases performed at a center, all the cases, or only the most recent. This could have dramatic 
implications, especially for the complication rates, which would be expected to decrease with experience. These issues leave the 
study with no protection from confounding variables, and expose it to a myriad of selection biases. The differentiation between 
major and minor complications in this study is reasonable; however, it would be helpful to know how long an observational period 
or hospital stay must be before it is considered prolonged. This would allow better understanding of the complication rate, and 
would help make it more generalizable, because the standard practice for length of hospitalization or observation can vary based on 
geographical area and over time. 
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Another unfortunate limitation is that there is no comparison or mention of the complication rate for other definitive diagnostic 
procedures in similar patients. This makes the study less useful when trying to decide the best procedure to diagnose a splenic lesion. 
From the 398 cases reviewed, the numbers needed to harm (NNH) for major (3), minor (18), and total complications (21) were 132, 
22, and 19 respectively. In other words, 132 percutaneous image-guided splenic biopsies would need to be performed, on average, 
for one patient to experience a major complication. However, these numbers are not particularly useful because the biopsy is being 
compared to no biopsy with an assumed complication rate of zero. The appropriate comparator for this calculation is the number of 
complications due to a lack of diagnosis, which is unknown. As calculated, the NNH does give a partial effect size about the risk of 
the procedure itself. 
Additionally, the positive and negative likelihood ratios help illuminate the diagnostic value of splenic biopsies. They were 113.8 
[95% CI, 28.6-453.1] and 0.10 [95% CI, 0.06-0.16] respectively. This means that a patient similar to ours with a low pretest 
probability of lymphoma (5%) would have an 86% post-test probability with a positive test or 0.5% with a negative test. This 
highlights the usefulness of splenic biopsies as diagnostic tests and shows the benefit may outweigh the risk even with the low 
possibility of complication. 
The study earns a Level of Evidence of Level 3 from the Oxford Centre for Evidence-Based Medicine 2014. It attempts to answer 
questions about the efficacy of a diagnostic test and how frequently complications occur. For examination of the diagnostic value, 
only a small proportion of the cases had a gold standard to compare to, and 80.4% were controlled with follow-up data. The 
frequency of complications was determined by a non-random local sample also consistent with Level 3 evidence. 
 
Clinical Application 
While the study may not have been ideally designed, it does reveal an area where theory and assumptions of risk 
may be guiding treatment rather than available evidence. This research is of critical importance to patients, 
because they cannot make an informed decision to undergo a procedure without knowing the risks. Also, 
physicians may be under-performing these biopsies because the conventional wisdom and historical use of larger 
bore needles5 has led to widespread overestimation of the complication rate. This may lead to significant 
morbidity and mortality through the potential delay in diagnosis, worse prognosis at discovery, or subjection to 
procedures that place patients at higher risk. If the findings of this paper were more widespread, it might have 
taken less time for our patient to get his splenic biopsy, and not required consulting a specific physician. This would 
have led to considerably less frustration on the part of our patient and potentially prevented him leaving AMA with 
an active C. difficile infection. Unfortunately, the result of his biopsy could not rule out lymphoma. However, he 
had no complications from the procedure. This highlights the safety of the procedure and that the possibility of 
additional testing needs to be addressed with patients undergoing any diagnostic test. 
Take Home Points: 
1.) The risks and benefits of all aspects of medicine should be evaluated objectively if possible. 
2.) Therapies that are widely considered safe or risky often lack sufficient objective high quality research to justify 
those beliefs. 
3.) Special effort must be made by physicians to determine if the patient is benefiting from subjective experiences 
or being harmed by unacknowledged biases. 
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